New EU action plan against AMR

30/06/2017 News Europe , Policy 2225 Views
New EU action plan against AMR

Yesterday June 29th, the European Commission launched its new European Union action plan to tackle antimicrobial resistance (AMR) – a growing threat that is responsible for 25,000 deaths in the EU every year.

The action plan is built around three pillars:

  •          Make Europe a best practice region.
  •          Boost research, development and innovation.
  •          Shape the global agenda.

Jaana Husu-Kallio, chairwoman of the European Food Safety Authority’ (EFSA) management board and also member of the UN Interagency Coordination Group on Antimicrobial Resistance, said: “Scientific evidence has shown that human health and animal health are interconnected. EFSA experts will continue to support the global fight against antimicrobial resistance by investigating the role of food and food-producing animals in transmitting antimicrobial resistance”.

The launch of the European Commission’ Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting this phenomenon, by proposing concrete and innovative solutions to benefit patients worldwide, according to a joint statement by the European Federation of Pharmaceutical Industries and Associations (EFPIA), European Biopharmaceutical Enterprises (EBE) and Vaccines for Europe

The industry’s commitment to combatting AMR is embodied in the Davos Declaration of January 2016, and the subsequent Industry Roadmap from September 2016. Against the backdrop of the European Commission’s Second Action Plan on AMR, we now call upon governments, multilateral institutions, the private sector and civil society to follow through on the momentum provided by the UN, G7, G20 and the 67 national AMR action plans, sponsored by governments around the world to implement concrete policy actions, they said

The research-based pharmaceutical industry underlines additionally the importance of dialogue between innovators and regulatory authorities to identify and create the necessary regulatory frameworks to support the development of innovative treatments and prophylactic strategies. Specifically for vaccines, a multi-stakeholder reflection would help identify where the regulatory framework should be adapted to accelerate access to vaccines targeting nosocomial pathogens.

“We will also need appropriate “pull” mechanisms, which reward the successful development of new antimicrobial medicines. Industry welcomes the Commission’s commitment to support research into the development of new economic models. Industry is keen to engage with Member State governments and the European Commission on the design of these models to address the risk and uncertainty that comes with the development of new antibiotics and vaccines,” the statement pointed out.

EFPIA director general Nathalie Moll said: “Industry is committed to playing its part in addressing this extremely urgent public health issue. All of industry, from SMEs to large companies, stands ready to invest in the fight against this alarming phenomenon. In order to enable this, we must create the right environment for investment in the fight against AMR. Ultimately, we cannot rely on innovation alone to solve the problem and will need a combination of scientific solutions and incentives, backed by sustained, collaborative stakeholder effort to get it right.”

About author

Related articles